Using Compounds in Breath to Identify End-stage Renal Disease

A simple, noninvasive test for kidney disease may be closer than we think, thanks to the work of researchers in the Glickman Urological & Kidney Institute and Respiratory Institute at Cleveland Clinic.

A team of physicians and researchers, led by critical care nephrologist Sevag Demirjian, MD; pulmonologist Raed Dweik, MD; and internal medicine resident Kelly Paschke, DO, has identified five chemical compounds present in the breath that have a high correlation with identification of end-stage renal disease.

“We have shown a proof of concept that it is possible to detect kidney disease through a breath test and without the need for a blood draw or laboratory analysis,” Dr. Demirjian reports. “These are very promising early results, and we hope to develop this into a practical tool in the coming years.”

VOCs provide clues

Their study, Molecular Breath Analysis Identifies the Breathprint of Renal Failure, published in the Journal of Breath Research, compared volatile organic compounds (VOCs) present in the breath of 86 patients known to have renal failure with the breath of 25 healthy controls using selected-ion flow-tube mass spectrometry (SIFT-MS).

Results of the full analysis show three known VOCs (2-propanol, ammonia and acetaldehyde) and two unnamed compounds (O2+ 50 and NO+ 76) are highly significant for identifying renal failure based on breath analysis.

Recent technological advances in VOC detection and spectral analysis have expanded into the hundreds the number of individual compounds detectable in the breath, Dr. Dweik explains. Furthermore, enhanced device sensitivity allows these compounds to be sniffed out and quantified in the range of parts-per-trillion. Dr. Dweik has been researching breath analysis for more than two decades.

Rapid-response breath test in the offing

“It’s similar to going from standard to high-definition television,” says Dr. Demirjian of recent improvements to the device. “The number of compounds we’re able to detect and the level of detail we’re able to see makes studies like this possible for the first time.”

Dr. Paschke believes that identification and validation of these compounds could lead to a rapid-response breath test to determine whether patients have kidney disease.

“This type of testing could have clinical implications for numerous patients, particularly because renal disease is often asymptomatic for many months,” says Dr. Paschke. “Applications of this research are far-reaching and could improve care in locations as diverse as Cleveland Clinic and community clinics in developing countries.”

Among the practical limitations of the technology is the sheer size of the testing device, says Dr. Demirjian. However, Drs. Demirjian, Dweik and Paschke are hopeful that technical hurdles can be overcome and devices miniaturized—especially now that evidence exists for a diverse and meaningful clinical impact.